RenovoRx’s PanTheR Registry Trial: A Promising Update for Investors

Renovorx, Inc. ((RNXT)) announced an update on their ongoing clinical study.

Study Overview: The PanTheR Registry Trial, officially titled A Multi-Center, Observational, Post-Marketing, Registry Study Following Patients With Solid Tumors Treated With Therapeutic Agents Via Localized Intra-Arterial Delivery Using the RenovoCath® Catheter, aims to track the safety and performance of the RenovoCath® device. This study focuses on assessing survival outcomes in patients with solid tumors treated through localized intra-arterial delivery of therapeutic agents, highlighting its significance in real-world clinical settings.

Intervention/Treatment: The study tests the RenovoCath® device, a catheter designed for intra-arterial delivery of chemotherapy agents. Its purpose is to provide targeted treatment to solid tumors, allowing for the collection of real-world data on its effectiveness and safety.

Study Design: This observational study follows a case-only model with a prospective time perspective. It is a patient registry study, meaning it collects data from patients who are receiving or have received treatment with the RenovoCath® device, focusing on real-world clinical outcomes without any masking or allocation interventions.

Study Timeline: The study began on August 1, 2025, with recruitment currently ongoing. Its primary completion and estimated completion dates are not specified, but the study is expected to continue for six years. The last update was submitted on August 14, 2025, indicating the study’s active status.

Market Implications: This update could impact RenovoRx’s stock performance positively by demonstrating the potential of the RenovoCath® device in improving patient outcomes. Investors may view this as a promising development, especially in the competitive oncology device market, potentially enhancing investor sentiment and interest in the company.

The study is ongoing, with further details available on the ClinicalTrials portal.